Depression and Suicide Risk in Oncologists: Daniel C. McFarland, DO

​ Physicians have the highest suicide rate of any profession, and oncologists experience depression at a higher rate than physicians in other internal medicine specialties. In this interview with i3 Health, Daniel C. McFarland, DO, a medical oncologist and psychiatrist at Memorial Sloan Kettering Cancer Center in New York City, discusses the factors contributing to this issue, which he and colleagues addressed in a recent publication of the American Society of Clinical Oncology (ASCO) and about ...
Continue reading

Portable Device Assesses Targeted Therapy’s Effectiveness

​ Researchers have developed a portable system that quickly determines an individual patient's response to targeted cancer therapy. "Our technology combines artificial intelligence and sophisticated biosensors that handle tiny amounts of fluids to see if cancer cells are sensitive or resistant to chemotherapy drugs," commented Mehdi Javanmard, PhD, Assistant Professor of Electrical and Computer Engineering at Rutgers University–New Brunswick and senior author of the study, which has now been pub...
Continue reading

Ibrutinib/Venetoclax Promising in Relapsed/Refractory CLL

​ CLARITY, a phase 2 clinical trial, reports that the combination of ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia (CLL) produces minimal residual disease (MRD)-negative responses, with promising rates of progression-free and overall survival. While some patients with CLL have indolent disease, for which treatment is not needed, others experience an aggressive progression of their cancer. For these patients, chemoimmunotherapy treatments such as fludarabine/cyclop...
Continue reading

NSCLC: Pembrolizumab Following Locally Ablative Therapy

​ A phase 2 clinical trial reports that the addition of pembrolizumab (Keytruda®, Merck) following locally ablative therapy for oligometastatic non-small cell lung cancer (NSCLC) improves median progression-free survival compared with historical data. About 7% of patients with NSCLC have oligometastatic disease, a state of limited systemic metastasis that could be cured by means of locally ablative therapy. A treatment consisting of surgery and radiation at all sites of metastasis, locally ablat...
Continue reading

Herpes Zoster (Shingles) Vaccination After Autologous HSCT

​ A phase 3 clinical trial reports that two doses of the adjuvanted recombinant zoster vaccine reduce the incidence of herpes zoster, commonly known as shingles, following autologous hematopoietic stem cell transplantation (HSCT). Patients receiving high-dose chemotherapy for certain types of malignancies, including multiple myeloma, non-Hodgkin lymphoma, Hodgkin lymphoma, acute myeloid leukemia, neuroblastoma, and germ cell tumors, are often administered autologous HSCT in order to replenish th...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.